SBIR/STTR Research Award

A LOW VOLTAGE ELECTROPORATION FOR GENE TRANSFER

Award identifier 0399d3c54d73075c270d887d3a2ce818b22ec51cdde494446245549e5e5f1b63Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$0

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PORE SQUARED BIOENGINEERING
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Verbatim from Applicant's Abstract): Our goal is to construct a prototype chamber with protocols for the manufacture of a new low-voltage electroporation (LVEP) system to transfect suspended and adherent cells under physiologic conditions. Electric field amplification results from embedding the cells into the pores of thin (13 um) insulating filters, enabling all 0.33 million to be simultaneously electroporated using 5-20 V across a 2 cm gap. The use of low voltage/current is the key to this new technique. The large increase in current density in the pores, produced by the reduction of current shunt pathways around each embedded cell, amplifies the localized field across the filter 1000X. LVEP produces minimal Joule heating and electrode products as the current is only 25 - 50 mA versus 25 - 50 A in suspension electroporation. Further, only one side of the cell, at the end of the cell process inside the pore, is electroporated. The transmembrane potential of the membrane hemisphere in the pore is constant, thus, the entire area reaches the same potential. The Phase I study demonstrated that LVEP can transfect mammalian cells with 93-98% cell viability, with transfection efficiencies of 5-80% of embedded cells. In Phase II, we will optimize the chamber characteristics and protocols to transfect genes into both adherent and suspended cells to maximize transfection efficiency, cell survival and ease of use. Different plasmids and cells will be examined, including primary cell lines. Important goals are to transfect cell lines proven difficult and demonstrate capability where high cell survival is necessary. PROPOSED COMMERCIAL APPLICATION: Not Available

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.